You are here: Industry Insights > Antibiotic

News List

Effective effluent management: Key to tackle AMR expresspharma
December 29, 2020
As the world adjusts to the post-COVID-19 reality, it is time to reflect and reset. It cannot be ‘business as usual’ in the struggle to survive.
Shionogi’s novel antibiotic added to UK’s pilot subscription reimbursement model pharmatimes
December 24, 2020
Shionogi’s novel antibiotic Fetcroja (cefiderocol) has been selected by the UK’s National Institute for Health and Care Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) to be included in a pilot subscription ...
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics prnasia
December 22, 2020
Alterity Therapeutics has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat antimicrobial resistance in superbugs.
Novel antibiotic shows promise in Phase II C. difficile study europeanpharmaceuticalreview
November 23, 2020
Ibezapolstat cured all 10 patients of their Clostridioides difficile infections and prevented recurrence for at least 30 days.
Scientists develop faster method to detect antibiotic resistance expresspharma
November 05, 2020
Researchers from the EPSRC-funded interdisciplinary research collaboration, i-sense have developed a new, a quicker way of detecting antibiotic-resistant bacteria.
COVID-19 heart changes raise death risk; virus may be lead killer of young adults during surges expresspharma
October 27, 2020
A new study may help identify which COVID-19 patients with signs of heart injury are at higher risk for death. Doctors looked at 305 hospitalised patients with elevated levels of troponin, a protein released when the heart has been injured.
Shionogi launches novel antibiotic Fetcroja in the UK pharmatimes
September 16, 2020
Japanese pharma company Shionogi has announced that its new antibiotic Fetcroja (cefiderocol) is now available for use in the UK, the first country to launch the drug following its European Commission (EC) approval earlier this year.
GARDP and Bugworks sign MoU to develop antibiotics for serious bacterial infections expresspharma
August 31, 2020
The collaboration includes working together for the preparation of regulatory strategies, in particular for clinical development programmes and post-approval studies.
MicuRx Commits Funding for Development of MRX-8 americanpharmaceuticalreview
August 18, 2020
MicuRx Pharmaceuticals announced the global partnership Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has committed up to US$7.78 million of nondilutive financing for a Phase 1 clinical trial and related R&D activities ...
Destiny Pharma’s novel antibiotic asset clears safety review pharmatimes
August 12, 2020
Brighton, UK-based Destiny Pharma has announced a positive interim safety review of its ongoing Phase IIb study of its lead antibiotic asset XF-73.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page